67 publications
| Name | Date | Type | Actions |
|---|---|---|---|
Monthly information regarding the total number of voting rights – February 2025
|
Voting rights | ||
Buyback programs - February 2025 Monthly communication regarding buyback programs |
Liquidity contract , Description of buyback programs | ||
Buyback programs - January 2025 Monthly communication regarding buyback programs |
Liquidity contract , Description of buyback programs | ||
Monthly information regarding the total number of voting rights – January 2025
|
Voting rights | ||
Annual sales 2024: €539 million Annual sales: €539 million (up 2.2% at constant exchange rates and up 1.9%. on a reported basis) |
Public releases | ||
2025 Calendar of financial communication Vetoquinol published its calendar of financial communication for 2025. |
Agenda | ||
Monthly information regarding the total number of voting rights – December 2024
|
Voting rights | ||
Buyback programs - December 2024 Monthly communication regarding buyback programs |
Liquidity contract , Description of buyback programs | ||
Vétoquinol continues to launch reference products Lure (France), December 16, 2013 – In line with its strategy of developing products targeting fast-growing markets, the Vétoquinol Group expands its Flexadin® range world-wide and launches Zylkène® in the United States. |
Public releases | ||
Monthly information regarding the total number of voting rights and shares making of the share capital - November 2013 As per article 223.16 of the « Règlement Général de l’Autorité des Marchés Financiers » |
Voting rights |